Wallace, Daniel J <br/><br/>
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Jul 2013 
 - 1313-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/ket129  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Male<br/>Middle Aged<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult